Laboratory findings.

1<p>Not available.</p>2<p>8:00 am measurement.</p>3<p>Vidia Biomérieux.</p>4<p>Vidas Biomérieux.</p

Genotyping results of BRC TgH41001 strain and 12 reference strains with 15 microsatellite markers.

1<p>PTG is a clone of the ME49 strain; CTG is also known as CEP or C strain; COUGAR is also known as TgCgCa1 or COUG strain; BRC TgH18001 is also known as GUY-DOS or GUY-2001-DOS strain; BRC TgH18002 is also known as GUY-KOE or GUY-2002-KOE strain; BRC TgH18003 is also known as GUY-MAT or GUY-2002-MAT.</p

Kaplan-Meier plots of the risk of disease relapse following rituximab in 31 IgG4-RD responding patients.

<p>Kaplan-Meier plots of the risk of disease relapse following rituximab in 31 IgG4-RD responding patients.</p

Kaplan-Meier plots of the risk of disease relapse following rituximab for patients with IgG4-RD RI >9 and with IgG4-RD RI ≤9 at RTX treatment.

<p>IgG4-RD RI, IgG4-related disease Responder Index.</p

Clinical, biological and radiological efficacy of RTX in 33 patients with IgG4-RD.

<p>Clinical, biological and radiological efficacy of RTX in 33 patients with IgG4-RD.</p

Hazard ratio for risk of flare: Unadjusted Cox regressions.

<p>Hazard ratio for risk of flare: Unadjusted Cox regressions.</p

Kaplan-Meier plots of the risk of disease relapse following rituximab for patients with IgG4-RD RI >9 and with IgG4-RD RI ≤9 at RTX treatment.

<p>IgG4-RD RI, IgG4-related disease Responder Index.</p

Risk of disease relapse following rituximab for patients with glucocorticoid and without glucocorticoid maintenance therapy at last follow-up or relapse.

<p>Risk of disease relapse following rituximab for patients with glucocorticoid and without glucocorticoid maintenance therapy at last follow-up or relapse.</p